How safe are TCR therapies for solid tumors?
TCR therapies are relatively safe, with manageable side effects that are less severe than those seen in blood cancer treatments. A meta-analysis of 566 patients with solid tumors found that only 3.8% experienced severe (grade 3 or higher) cytokine release syndrome (CRS), a common immune overreaction, and just 2.1% had severe neurotoxicity [2]. For comparison, patients with blood cancers treated with similar cell therapies had significantly higher rates of these complications (7.3% severe CRS and 13.9% severe neurotoxicity) [2]. In the largest single trial here—a phase 2 study of 52 patients with synovial sarcoma—71% had some degree of CRS, but only one case was severe (grade 3), and there were no treatment-related deaths [1]. A smaller early study of 8 patients with advanced solid tumors reported only one case of grade 3 CRS and no neurotoxicity at all [3]. Even in a different context—HIV treatment—a phase 1 trial of a TCR-like therapy in 8 participants found no serious adverse events and only mild side effects [4]. The consistent message across these studies is that severe immune reactions are uncommon and usually manageable.
Do TCR therapies produce lasting responses?
Durable responses are possible, but they are not guaranteed and depend on the cancer type and how well the therapy targets the tumor. The strongest evidence for durability comes from the phase 2 SPEARHEAD-1 trial, where 52 patients with advanced synovial sarcoma received a single infusion of afami-cel. After a median follow-up of 32.6 months (nearly 3 years), 37% of patients had their tumors shrink or disappear (overall response rate), and the responses were lasting [1]. In a striking case report, a patient with metastatic pancreatic cancer who received TCRs targeting a mutant protein (KRAS G12D) had a 72% reduction in tumor size that was still ongoing at 6 months, and the engineered T cells remained in the blood at high levels for that entire period [5]. A small multi-center study of 8 heavily pretreated patients reported a 50% response rate and a median event-free survival of 7 months, though follow-up was shorter at 9 months [3]. However, the meta-analysis tempers this optimism: across all solid tumor patients, the overall response rate was only 20.1%, and clinical benefit (response or stable disease) was 62.6% [2]. So while some patients achieve durable remissions, many do not respond at all.
Which patients are most likely to benefit?
The evidence points to better outcomes when the therapy targets a specific, cancer-driving antigen and when the patient's tumor type is known to be sensitive. In the meta-analysis, TCR therapies targeting the NY-ESO-1 antigen had double the odds of producing a response compared to other targets [2]. The phase 2 trial of afami-cel was limited to patients whose tumors expressed the MAGE-A4 antigen and who had the HLA-A*02 immune type, and it achieved a 39% response rate in synovial sarcoma specifically [1]. The pancreatic cancer case succeeded because the TCRs targeted the KRAS G12D mutation, a common driver of that cancer [5]. Conversely, the meta-analysis found that overall response rates in solid tumors (20.1%) were far lower than in blood cancers (75.4%), meaning many solid tumor patients do not respond [2]. The small study targeting TP53, KRAS, and CEA antigens in 8 patients showed a 50% response rate, but this is too small to generalize [3]. In short, the best candidates are those with tumors that express a well-defined, targetable antigen and who have a compatible immune type (HLA), but even then, response is not guaranteed.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2026, 2 from 2024 or later, 5 in Q1 journals, collectively cited 686 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 57 papers retrieved from a database of over 500 million.
Sources used in this answer
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
In a phase 2 trial of 52 patients with advanced synovial sarcoma or myxoid round cell liposarcoma, afami-cel produced a 37% overall response rate with durable responses (median follow-up 32.6 months) and no treatment-related deaths, showing TCR therapy can safely target solid tumors.
Abstract 2764: Safety and efficacy of CAR T and TCR therapies in solid tumors: A systematic review and meta-analysis, including a comparison with five phase II trials in hematologic malignancies used for the first FDA approvals of these agents
A meta-analysis of 566 solid tumor patients receiving CAR T or TCR therapies found severe CRS in only 3.8% and severe neurotoxicity in 2.1%, but overall response rates were modest at 20.1%—lower than in blood cancers (75.4%).
Early experience with T-cell receptor cellular therapy in advanced solid malignancies: A multi-center analysis of safety and efficacy.
In a small multi-center study of 8 heavily pretreated patients with advanced solid tumors, TCR therapy achieved a 50% objective response rate and 75% disease control rate, with only one case of grade 3 CRS and no neurotoxicity.
Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial
A phase 1 trial of AGT103-T (a TCR-like therapy for HIV) in 8 participants found no serious adverse events, and genetically modified cells persisted in blood for at least 6 months, with Gag-specific T cell responses increased 9- to 300-fold.
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
A single patient with metastatic pancreatic cancer treated with TCRs targeting mutant KRAS G12D had a 72% tumor regression ongoing at 6 months, with engineered T cells persisting at high levels in the blood.